
OKUR Stock Forecast & Price Target
OKUR Analyst Ratings
Bulls say
OnKure Therapeutics Inc demonstrated a narrower-than-expected net loss of $1.14 per share for 2Q25, indicating improved financial performance relative to estimates. Additionally, the clinical trials for OKI-219 showed positive safety profiles, with the treatment being well-tolerated and no significant adverse events reported, which bodes well for future development. The combination of reduced losses and promising clinical results underpins a positive outlook for the company as it continues to advance its precision medicine initiatives in the cancer treatment space.
Bears say
OnKure Therapeutics Inc. is projected to incur a net loss of $4.56 per share for the full year 2025, which reflects a slight improvement from a prior estimate of $4.75 per share. The company faces several significant risks, including the potential for negative clinical results associated with its lead asset, OKI-219, and possible delays in advancing its pipeline candidates to regulatory approval stages. Additionally, competitive pressures from other mutant-selective PI3Kα inhibitors and the risk of long-term shareholder dilution contribute to a challenging outlook for the company's financial stability.
This aggregate rating is based on analysts' research of OnKure Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
OKUR Analyst Forecast & Price Prediction
Start investing in OKUR
Order type
Buy in
Order amount
Est. shares
0 shares